Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study

ABSTRACT Introduction Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used in the treatment of non‐small cell lung cancer (NSCLC). Preclinical studies suggest inflammatory and other mechanisms of analgesics affect the efficacy of EGFR TKIs. In this study, we aim to expl...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura S. Puuniemi, Sanna M. E. Iivanainen, Martti Arffman, Riitta L. Kaarteenaho, Jussi P. Koivunen
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.71040
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849707643518582784
author Laura S. Puuniemi
Sanna M. E. Iivanainen
Martti Arffman
Riitta L. Kaarteenaho
Jussi P. Koivunen
author_facet Laura S. Puuniemi
Sanna M. E. Iivanainen
Martti Arffman
Riitta L. Kaarteenaho
Jussi P. Koivunen
author_sort Laura S. Puuniemi
collection DOAJ
description ABSTRACT Introduction Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used in the treatment of non‐small cell lung cancer (NSCLC). Preclinical studies suggest inflammatory and other mechanisms of analgesics affect the efficacy of EGFR TKIs. In this study, we aim to explore the outcomes of concurrent use of EGFR TKIs and analgesics, to provide clinical insight into analgesic treatment decisions. Methods Patients (n = 1494) with EGFR TKI reimbursements (2011–2020) and data available in the Finnish Cancer Registry with concurrent analgesics purchases (nonsteroidal anti‐inflammatory drugs [NSAID], acetaminophen, weak and strong opioids, strong opioids stratified by immunomodulatory properties) were identified. Overall survival (OS) and time‐on‐treatment (ToT) were analyzed using univariate and multivariate Cox models and Kaplan–Meier. Results In multivariate analysis for ToT, weak and strong opioids were associated with inferior outcomes (HR 1.368, 95% CI 1.119–1.674, HR 1.454, 95% CI 1.276–1.656) compared to no analgesics, while NSAID and acetaminophen showed no association. Multivariate analysis for OS showed inferior survival among EGFR TKI‐treated patients with weak (HR 1.290, 95% CI 1.043–1.595) and strong opioid (HR 1.690, 95% CI 1.471–1.940) purchases, while this was not seen with NSAID. Compared to nonimmunomodulatory opioids, patients with immunomodulatory opioid purchases had unfavorable outcomes for both ToT (HR 1.448, 95% CI 1.148–1.826) and OS (HR 1.479, 95% CI 1.158–1.888). Conclusions In EGFR TKI‐treated NSCLC, opioids are an independent risk factor for worse ToT and OS. The outcomes differed by immunomodulatory category of opioids, suggesting analgesics class can potentially have an impact on EGFR TKI effects.
format Article
id doaj-art-750b8077dd40482f8d75e93065c20d0a
institution DOAJ
issn 2045-7634
language English
publishDate 2025-07-01
publisher Wiley
record_format Article
series Cancer Medicine
spelling doaj-art-750b8077dd40482f8d75e93065c20d0a2025-08-20T03:15:52ZengWileyCancer Medicine2045-76342025-07-011413n/an/a10.1002/cam4.71040Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based StudyLaura S. Puuniemi0Sanna M. E. Iivanainen1Martti Arffman2Riitta L. Kaarteenaho3Jussi P. Koivunen4Research Unit of Cancer and Translational Medicine, Cancer Center, Medical Research Center (MRC) Oulu University of Oulu and Oulu University Hospital Oulu FinlandResearch Unit of Cancer and Translational Medicine, Cancer Center, Medical Research Center (MRC) Oulu University of Oulu and Oulu University Hospital Oulu FinlandDepartment of Public Health and Welfare Finnish Institute for Health and Welfare Helsinki FinlandResearch Unit of Biomedicine and Internal Medicine, Center of Internal Medicine and Respiratory Medicine, Medical Research Center (MRC) Oulu Oulu University Hospital, University of Oulu Oulu FinlandResearch Unit of Cancer and Translational Medicine, Cancer Center, Medical Research Center (MRC) Oulu University of Oulu and Oulu University Hospital Oulu FinlandABSTRACT Introduction Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used in the treatment of non‐small cell lung cancer (NSCLC). Preclinical studies suggest inflammatory and other mechanisms of analgesics affect the efficacy of EGFR TKIs. In this study, we aim to explore the outcomes of concurrent use of EGFR TKIs and analgesics, to provide clinical insight into analgesic treatment decisions. Methods Patients (n = 1494) with EGFR TKI reimbursements (2011–2020) and data available in the Finnish Cancer Registry with concurrent analgesics purchases (nonsteroidal anti‐inflammatory drugs [NSAID], acetaminophen, weak and strong opioids, strong opioids stratified by immunomodulatory properties) were identified. Overall survival (OS) and time‐on‐treatment (ToT) were analyzed using univariate and multivariate Cox models and Kaplan–Meier. Results In multivariate analysis for ToT, weak and strong opioids were associated with inferior outcomes (HR 1.368, 95% CI 1.119–1.674, HR 1.454, 95% CI 1.276–1.656) compared to no analgesics, while NSAID and acetaminophen showed no association. Multivariate analysis for OS showed inferior survival among EGFR TKI‐treated patients with weak (HR 1.290, 95% CI 1.043–1.595) and strong opioid (HR 1.690, 95% CI 1.471–1.940) purchases, while this was not seen with NSAID. Compared to nonimmunomodulatory opioids, patients with immunomodulatory opioid purchases had unfavorable outcomes for both ToT (HR 1.448, 95% CI 1.148–1.826) and OS (HR 1.479, 95% CI 1.158–1.888). Conclusions In EGFR TKI‐treated NSCLC, opioids are an independent risk factor for worse ToT and OS. The outcomes differed by immunomodulatory category of opioids, suggesting analgesics class can potentially have an impact on EGFR TKI effects.https://doi.org/10.1002/cam4.71040EGFR TKINSAIDNSCLCopioid
spellingShingle Laura S. Puuniemi
Sanna M. E. Iivanainen
Martti Arffman
Riitta L. Kaarteenaho
Jussi P. Koivunen
Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
Cancer Medicine
EGFR TKI
NSAID
NSCLC
opioid
title Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
title_full Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
title_fullStr Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
title_full_unstemmed Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
title_short Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
title_sort concomitant use of analgesics and egfr tkis in lung cancer patients outcomes and perspectives from a finnish retrospective register based study
topic EGFR TKI
NSAID
NSCLC
opioid
url https://doi.org/10.1002/cam4.71040
work_keys_str_mv AT lauraspuuniemi concomitantuseofanalgesicsandegfrtkisinlungcancerpatientsoutcomesandperspectivesfromafinnishretrospectiveregisterbasedstudy
AT sannameiivanainen concomitantuseofanalgesicsandegfrtkisinlungcancerpatientsoutcomesandperspectivesfromafinnishretrospectiveregisterbasedstudy
AT marttiarffman concomitantuseofanalgesicsandegfrtkisinlungcancerpatientsoutcomesandperspectivesfromafinnishretrospectiveregisterbasedstudy
AT riittalkaarteenaho concomitantuseofanalgesicsandegfrtkisinlungcancerpatientsoutcomesandperspectivesfromafinnishretrospectiveregisterbasedstudy
AT jussipkoivunen concomitantuseofanalgesicsandegfrtkisinlungcancerpatientsoutcomesandperspectivesfromafinnishretrospectiveregisterbasedstudy